Compare BELFA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFA | MESO |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | United States | Australia |
| Employees | 4964 | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | N/A |
| Metric | BELFA | MESO |
|---|---|---|
| Price | $231.50 | $15.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $174.25 | N/A |
| AVG Volume (30 Days) | 68.1K | ★ 188.2K |
| Earning Date | 04-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.74 | $629.74 |
| Revenue Next Year | $6.34 | $30.65 |
| P/E Ratio | $40.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.00 | $9.88 |
| 52 Week High | $255.04 | $21.50 |
| Indicator | BELFA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 52.51 |
| Support Level | $114.22 | $15.62 |
| Resistance Level | N/A | $16.37 |
| Average True Range (ATR) | 11.29 | 0.39 |
| MACD | -0.34 | 0.01 |
| Stochastic Oscillator | 57.44 | 51.72 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.